The PALLD Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes with targeted disruption of the PALLD gene. This loss-of-function model enables investigation of palladin??s role in actin cytoskeleton organization, cell adhesion, and migration. As a polyclonal knockout, the product contains a heterogeneous allele mix, avoiding clonal selection artifacts and providing a robust platform for functional assays.
Raji cells originate from a Burkitt lymphoma patient and are Epstein-Barr virus (EBV)-positive lymphoblastoid B lymphocytes. They serve as a classic model for B-cell biology, humoral immunity, and lymphomagenesis. Their rapid proliferation and expression of B-cell markers facilitate studies of immunoglobulin production, antigen presentation, and viral oncoprotein-driven transformation, making them highly relevant for immunological and cancer research.
Palladin is an actin-crosslinking protein regulated by Rho GTPases (RhoA, Rac1, Cdc42) and integrin/TGF-beta signaling. It directly interacts with ??-actinin, VASP, Eps8, Ezrin, Profilin, and actin, linking these factors to focal adhesion dynamics. Downstream, palladin modulates actin remodeling and FAK phosphorylation, which are critical for cell motility and adhesion. Thus, PALLD disruption disrupts Rho GTPase-driven cytoskeletal rearrangements.
In Raji B lymphoblasts, palladin is implicated in controlling the actin cytoskeleton required for cell migration and invasion. Knockout of PALLD impairs focal adhesion turnover and reduces motility, potentially impacting lymphoma cell dissemination. This model therefore allows dissection of cytoskeletal contributions to B-cell malignancy, including processes relevant to metastasis and tissue infiltration.
Key applications include live-cell imaging of F-actin dynamics, transwell migration assays, and immunofluorescence analysis of focal adhesions. Western blotting for PALLD and phospho-FAK, flow cytometry for integrins, and RNA-seq transcriptomic profiling enable comprehensive characterization. This knockout cell pool supports anti-metastatic drug screening, Rho GTPase pathway studies, and B-cell lymphoma research. For inquiries, contact Ascent Research.
